Abstract
Gemcitabine is a pyrimidine analog of deoxycytidine with activity against nonhematologic and hematologic malignancies. Its pulmonary toxicity is usually mild and self-limiting. We describe a male patient with lung cancer in whom severe dyspnea and interstitial infiltrates developed after the administration of gemcitabine.
Original language | English (US) |
---|---|
Pages (from-to) | 31-33 |
Number of pages | 3 |
Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
Volume | 25 |
Issue number | 1 |
DOIs | |
State | Published - 2002 |
Keywords
- Gemcitabine
- Pulmonary toxicity
ASJC Scopus subject areas
- Oncology
- Cancer Research